Warner-Lambert agrees to stop production

Segal, Marian
January 1994
FDA Consumer;Jan/Feb94, Vol. 28 Issue 1, p38
Reports that the Warner-Lambert Company agreed in August 1993 to stop making a wide range of drug products until it complied with federal regulations for good manufacturing practices. Terms of the consent decree; List of prescription drugs that remained in production; Discussion of problems found throughout the company's operations; More.


Related Articles

  • National ink.  // Business News New Jersey;10/06/97, Vol. 10 Issue 34, p3 

    Focuses on Lipitor a drug used in fight cholesterol which is distributed by Warner-Lambert. Information on the marketing of the drug; Examination of the therapeutic uses of the drug; Comments from chief executive officer, Melvin R. Goodes.

  • Listerine shapes up with PET barbell.  // Packaging Digest;Aug94, Vol. 31 Issue 9, p1 

    Reports on Warner-Lambert Co.'s repackaging of its Listerine mouthwash using polyethylene terephthalate (PET) bottles. Reasons for the company's decision; Features of the enhanced packaging design; Incorporation of child-resistant (C-R) push-and-turn closures.

  • Warner-Lambert realigns.  // Snack Food;Jan95, Vol. 84 Issue 1, p13 

    Reports on Warner-Lambert's realignment of its consumer healthcare and confectionery sectors due to continued strength and growth. Company's claimed achievement of a critical mass in the pharmaceutical, consumer health and confectionery operations; Establishment of a new confectionery division.

  • Add Parke-Davis. Muirhead, Greg // Drug Topics;11/7/94, Vol. 138 Issue 21, p74 

    Reports on the creation of the Parke-Davis Health Care Systems division at Warner-Lambert Co. to develop disease management programs.

  • Fix it or get out.  // Northern New Jersey Business;4/19/95, Vol. 3 Issue 8, p3 

    Reports that Warner-Lambert is serious about improving the performance of its troubled pharmaceutical business. Plans for new drugs.

  • Hot prospect.  // Northern New Jersey Business;9/6/95, Vol. 3 Issue 18, p3 

    Reports on financial analysts' view on the vulnerability of drug company Warner-Lambert to a takeover. Diversification into non-drug fields as the company's weakness; Talk of a merger between Warner-Lambert and Schering-Plough.

  • Creative downsizing.  // Personnel Journal;Sep92, Vol. 71 Issue 9, Human Resource Supplement p8 

    Examines how Warner Lambert's New Jersey corporate headquarters, as part of a worldwide restructuring effort, eliminated several secretarial and administrative assistant positions. How the company then developed a program that met the economic needs of both the organization and the displaced...

  • W-L Doles $125M to Zantac, resets Rolaids. Mehegan, Sean // Brandweek;4/22/96, Vol. 37 Issue 17, p5 

    Reports on Warner-Lambert's advertising strategy for its Zantac 75 heartburn remedy. Review of brand management for first-generation antacid Rolaids; Amount spent for promotions; Challenges faced by Warner-Lambert.

  • Clorets takes on Smint with `mini mint' brand.  // Marketing Week;6/18/1998, Vol. 21 Issue 16, p11 

    Reports on the launch of Clorets Powerful Mints by the Warner Lambert company. When the mints are scheduled to be launched; Estimated cost of the mints; Details on the launch of mini mints by the Nestle company; Name of the advertising agency used by Warner.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics